Eur Neuropsychopharmacol. 2007 May-Jun;17(6-7):440-7.
Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial.
Wozniak J, Biederman J, Mick E, Waxmonsky J, Hantsoo L, Best C, Cluette-Brown JE, Laposata M.
Pediatric Psychopharmacology Research Unit, Massachusetts General Hospital, Boston, MA 02138, USA. firstname.lastname@example.org
BACKGROUND: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite(R) brand) in the treatment of pediatric bipolar disorder (BPD). METHOD: Subjects (N=20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of >15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). RESULTS: Subjects experienced a statistically significant but modest 8.9+/-2.9 point reduction in the YMRS scores (baseline YMRS=28.9+/-10.1; endpoint YMRS=19.1+/-2.6, p<0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. CONCLUSIONS: 35% of these subjects had a 50% rapid reduction in mania on the YMRS. The 50% rapid reduction in mania on the YMRS on Omega-3 OmegaBrite compares to the same authors similar findings in olazapine with a 53% reduction. In that earlier study they authors used a success level of a 50% rapid reduction in the YMRS in 35% of the subjects for atypical antidepressants risperidol and olanzapine.